Overall, multidisciplinary approaches combining molecular biology, pharmacology, and clinical research are necessary to realize the therapeutic potential of targeting SLC7A11 in pancreatic fibrosis and pancreatic cancer. This evidence concerns the gene SLC7A11 and familial pancreatic carcinoma.